External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

External broker reports(aggregated public sources)

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<div><div><div><ul><li>Clarity Pharmaceuticals’ Phase I/IIa SECuRE trial evaluating their 64Cu/67Cu-SAR-bisPSMA theranostic pair in metastatic castrate-resistant prostate cancer (mCRPC) has completed Cohort 2 and progresses to Cohort 3 enrolment.</li><li>Importantly, the responses of the three patients treated in Cohort 2 with a single 8GBq dose of CU6’s PSMA therapeutic asset (67Cu-SAR-bisPSMA) have shown material reductions in PSA levels (a key surrogate efficacy endpoint).</li><li>Two of the three patients experienced ~90% PSA reductions, which is an impressive response considering this is following just one 8GBq dose. </li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Clarity Pharmaceuticals’ Phase I/IIa SECuRE trial evaluating their 64Cu/67Cu-SAR-bisPSMA theranostic pair in metastatic castrate-resistant prostate cancer (mCRPC) has completed Cohort 2 and progresses to Cohort 3 enrolment.Importantly, the responses of the three patients treated in Cohort 2 with a single 8GBq dose of CU6’s PSMA therapeutic asset (67Cu-SAR-bisPSMA) have shown material reductions in PSA levels (a key surrogate efficacy endpoint).Two of the three patients experienced ~90% PSA reductions, which is an impressive response considering this is following just one 8GBq dose. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6)M - SECuRE Cohort 2 Data Impresses

<div><div><div><ul><li>We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and risked price target of $1.22/sh.</li><li>The company’s 67Cu manufacturing partner (NorthStar Medical Isotopes; NSMI) held a site tour last week in Wisconsin.</li><li>We attended to validate progress and to discuss matters of purification, yield, supply chain and regulatory pathways. </li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and risked price target of $1.22/sh.The company’s 67Cu manufacturing partner (NorthStar Medical Isotopes; NSMI) held a site tour last week in Wisconsin.We attended to validate progress and to discuss matters of purification, yield, supply chain and regulatory pathways. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - BEAM ON in Wisconsin

<div><div><div><ul><li>Clarity have announced that their exclusive manufacturing partner, NorthStar Radioisotopes, have successfully completed large scale manufacturing runs of their therapeutic radioisotope, 67- Copper, for use in Clarity’s ongoing clinical trial programs (SeCURE, COMBAT, CL04).</li><li>This is a huge milestone for Clarity and NorthStar with large scale production of this isotope being the key impediment to its development as a therapeutic isotope in years past.</li><li>Novel methods utilizing electron accelerator technology have enabled high purity, large scale 67-Cu isolation, which is critical to enable Clarity’s pipeline development across their prostate (PSMA-avid SeCURE; non- PSMA avid COMBAT) and Neuroblastoma (CL04) programs. </li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Clarity have announced that their exclusive manufacturing partner, NorthStar Radioisotopes, have successfully completed large scale manufacturing runs of their therapeutic radioisotope, 67- Copper, for use in Clarity’s ongoing clinical trial programs (SeCURE, COMBAT, CL04).This is a huge milestone for Clarity and NorthStar with large scale production of this isotope being the key impediment to its development as a therapeutic isotope in years past.Novel methods utilizing electron accelerator technology have enabled high purity, large scale 67-Cu isolation, which is critical to enable Clarity’s pipeline development across their prostate (PSMA-avid SeCURE; non- PSMA avid COMBAT) and Neuroblastoma (CL04) programs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - 67 Cu Is a Go!

<div><div><div><ul><li>Clarity have provided an update regarding their SeCuRE trial – the PSMA theranostic trial assessing the identification and treatment of metastatic, castrate-resistant prostate cancer (mCRPC) using Clarity’s 64Cu/67Cu-SAR-bisPSMA targeted copper theranostic (TCT) pair.</li><li>The release of the early data reveal is positive – there were no safety issues reported with 67Cu (at a 4GBq dose level), meaning that the trial can progress to Cohort 2 (utilizing an 8GBq dose).</li><li>Importantly, even with the lower dose used in Cohort 1, there is already evidence of clinical</li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Clarity have provided an update regarding their SeCuRE trial – the PSMA theranostic trial assessing the identification and treatment of metastatic, castrate-resistant prostate cancer (mCRPC) using Clarity’s 64Cu/67Cu-SAR-bisPSMA targeted copper theranostic (TCT) pair.The release of the early data reveal is positive – there were no safety issues reported with 67Cu (at a 4GBq dose level), meaning that the trial can progress to Cohort 2 (utilizing an 8GBq dose).Importantly, even with the lower dose used in Cohort 1, there is already evidence of clinicalContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - First Look at 67Cu Therapy Data

<ul><li>We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and risked price target of $1.22/sh.</li><li>Clarity have unveiled further detail from their Phase I/II PROPELLER trial with their prostate cancer diagnostic asset - 64Cu-SAR-bisPSMA.</li><li>Clarity announced in December the trial hit its primary endpoints, however today we see further detail regarding the safety profile and accuracy of the diagnostic versus the new standard of care (68Ga-PSMA-11). </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and risked price target of $1.22/sh.Clarity have unveiled further detail from their Phase I/II PROPELLER trial with their prostate cancer diagnostic asset - 64Cu-SAR-bisPSMA.Clarity announced in December the trial hit its primary endpoints, however today we see further detail regarding the safety profile and accuracy of the diagnostic versus the new standard of care (68Ga-PSMA-11). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - Clarity’s Copper Play Stacks up Vs New SOC

Australia

Clarity Pharmaceuticals Limited operates as a radio-pharmaceutical company. The Company focuses on the developing targeted therapies for the treatment of cancer and other serious diseases. Clarity Pharmaceuticals serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clarity Pharmaceuticals Ltd (CU6 AU)

Clarity Pharmaceuticals (CU6)M - SECuRE Cohort 2 Data Impresses

Two of the three patients experienced ~90% PSA reductions, which is an impressive response considering this is following just one 8GBq dose.

Wilsons Advisory

Clarity Pharmaceuticals (CU6) - BEAM ON in Wisconsin

The company’s 67Cu manufacturing partner (NorthStar Medical Isotopes; NSMI) held a site tour last week in Wisconsin. We attended to validate...

Wilsons Advisory

Clarity Pharmaceuticals (CU6) - 67 Cu Is a Go!

This is a huge milestone for Clarity and NorthStar with large scale production of this isotope being the key impediment to its development as a...

Wilsons Advisory

Clarity Pharmaceuticals (CU6) - First Look at 67Cu Therapy Data

The release of the early data reveal is positive – there were no safety issues reported with 67Cu (at a 4GBq dose level), meaning that the trial...

Wilsons Advisory

Clarity Pharmaceuticals (CU6) - Clarity’s Copper Play Stacks up Vs New SOC

Clarity have unveiled further detail from their Phase I/II PROPELLER trial with their prostate cancer diagnostic asset - 64Cu-SAR-bisPSMA.

Wilsons Advisory

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)